Cargando…

New Insights in the Setting of Transplant Oncology

Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Quaresima, Silvia, Melandro, Fabio, Giovanardi, Francesco, Shah, Kejal, De Peppo, Valerio, Mennini, Gianluca, Ghinolfi, Davide, Limkemann, Ashley, Pawlik, Timothy M., Lai, Quirino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058845/
https://www.ncbi.nlm.nih.gov/pubmed/36984569
http://dx.doi.org/10.3390/medicina59030568
_version_ 1785016732713222144
author Quaresima, Silvia
Melandro, Fabio
Giovanardi, Francesco
Shah, Kejal
De Peppo, Valerio
Mennini, Gianluca
Ghinolfi, Davide
Limkemann, Ashley
Pawlik, Timothy M.
Lai, Quirino
author_facet Quaresima, Silvia
Melandro, Fabio
Giovanardi, Francesco
Shah, Kejal
De Peppo, Valerio
Mennini, Gianluca
Ghinolfi, Davide
Limkemann, Ashley
Pawlik, Timothy M.
Lai, Quirino
author_sort Quaresima, Silvia
collection PubMed
description Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). Materials and Methods: A review of the recently published literature was conducted. Results: Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. Conclusion: For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT’s impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required.
format Online
Article
Text
id pubmed-10058845
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100588452023-03-30 New Insights in the Setting of Transplant Oncology Quaresima, Silvia Melandro, Fabio Giovanardi, Francesco Shah, Kejal De Peppo, Valerio Mennini, Gianluca Ghinolfi, Davide Limkemann, Ashley Pawlik, Timothy M. Lai, Quirino Medicina (Kaunas) Review Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). Materials and Methods: A review of the recently published literature was conducted. Results: Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. Conclusion: For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT’s impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required. MDPI 2023-03-14 /pmc/articles/PMC10058845/ /pubmed/36984569 http://dx.doi.org/10.3390/medicina59030568 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Quaresima, Silvia
Melandro, Fabio
Giovanardi, Francesco
Shah, Kejal
De Peppo, Valerio
Mennini, Gianluca
Ghinolfi, Davide
Limkemann, Ashley
Pawlik, Timothy M.
Lai, Quirino
New Insights in the Setting of Transplant Oncology
title New Insights in the Setting of Transplant Oncology
title_full New Insights in the Setting of Transplant Oncology
title_fullStr New Insights in the Setting of Transplant Oncology
title_full_unstemmed New Insights in the Setting of Transplant Oncology
title_short New Insights in the Setting of Transplant Oncology
title_sort new insights in the setting of transplant oncology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058845/
https://www.ncbi.nlm.nih.gov/pubmed/36984569
http://dx.doi.org/10.3390/medicina59030568
work_keys_str_mv AT quaresimasilvia newinsightsinthesettingoftransplantoncology
AT melandrofabio newinsightsinthesettingoftransplantoncology
AT giovanardifrancesco newinsightsinthesettingoftransplantoncology
AT shahkejal newinsightsinthesettingoftransplantoncology
AT depeppovalerio newinsightsinthesettingoftransplantoncology
AT menninigianluca newinsightsinthesettingoftransplantoncology
AT ghinolfidavide newinsightsinthesettingoftransplantoncology
AT limkemannashley newinsightsinthesettingoftransplantoncology
AT pawliktimothym newinsightsinthesettingoftransplantoncology
AT laiquirino newinsightsinthesettingoftransplantoncology